ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

311
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
bullishDada Nexus
29 Jan 2025 06:15

Dada Nexus (DADA US): JD.Com's US$2/ADS Non-Binding Offer

Given the indicative nature of JD.com's Offer, DADA is trading wide at a 11% gross spread to terms. I'd look to enter around here and on any pullback.

Logo
496 Views
Share
bullishRed Hawk Mining
28 Jan 2025 17:12

Red Hawk (RHK AU): Fortescue's Off-Market Offer

This is done. Trading tight at A$1.19/share. Payment under the Offer is 10 business days once unconditional. If in, stay in. If small, illiquid...

Logo
392 Views
Share
28 Jan 2025 12:53

Shandong Hi-Speed New Energy (1250 HK)'s Unconditional MGO Now Open

Assuming around mid-Feb payment, I'd pay up to HK$1.76/share. Don't expect a bump in terms. SDHG has taken advantage of Citic exiting.

Logo
470 Views
Share
bullishSLB Development
28 Jan 2025 11:51

SLB Dev (SLB SP): Ong Family Offer By Way Of A Scheme.

This is done. Trading tight at a 2.2%/7.2% gross/annualised spread, if payment late May. If small-cap illiquid arbs are your bent, get involved.

Logo
473 Views
Share
bearishWH Group
28 Jan 2025 09:16

WH Group (288 HK) Is Stretched As Smithfield Mulls IPO Price Reduction

A US$10bn market cap for Smithfield was punchy. Reportedly, the feedback from investors think likewise. Dumbing down the bottom end of the price...

Logo
501 Views
Share
x